摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Deoxy-D-ribitol | 13942-76-2

中文名称
——
中文别名
——
英文名称
2-Deoxy-D-ribitol
英文别名
(2R,3S)-pentane-1,2,3,5-tetrol
2-Deoxy-D-ribitol化学式
CAS
13942-76-2
化学式
C5H12O4
mdl
——
分子量
136.148
InChiKey
ZDAWZDFBPUUDAY-CRCLSJGQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    405.3±40.0 °C(Predicted)
  • 密度:
    1.336±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -2
  • 重原子数:
    9
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    80.9
  • 氢给体数:
    4
  • 氢受体数:
    4

SDS

SDS:d5ff862f8cdad5453abb2377b3925ba1
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-Deoxy-D-ribitol对甲苯磺酸 作用下, 以 甲苯 为溶剂, 反应 4.0h, 以68%的产率得到1,2-二脱氧-D-核糖
    参考文献:
    名称:
    NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
    摘要:
    本文揭示了公式(I)中的大麻素受体配体,其中A1、A5、Rx、X4和z如规范中定义。还公开了包含这些化合物的组合物,以及使用这些化合物和组合物治疗疾病和疾病的方法。
    公开号:
    US20100069348A1
  • 作为产物:
    描述:
    2-deoxy-D-ribose 在 sodium tetrahydroborate 作用下, 生成 2-Deoxy-D-ribitol
    参考文献:
    名称:
    Identification of the alkaline-labile product accompanying cytosine release during bleomycin-mediated degradation of d(CGCGCG)
    摘要:
    DOI:
    10.1021/ja00282a063
点击查看最新优质反应信息

文献信息

  • COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
    申请人:Carroll William A.
    公开号:US20100249129A1
    公开(公告)日:2010-09-30
    Disclosed herein are compounds of formula (I) wherein Ring A and R 1 are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions are also disclosed.
    本文揭示了以下式(I)的化合物 其中环A和R 1 如规范中所定义。还披露了包含这些化合物的药物组合物,以及使用这些化合物和药物组合物治疗疾病和疾病的方法。
  • Selective C−O Bond Cleavage of Sugars with Hydrosilanes Catalyzed by Piers’ Borane Generated In Situ
    作者:Jianbo Zhang、Sehoon Park、Sukbok Chang
    DOI:10.1002/anie.201708109
    日期:2017.10.23
    [(C6F5)2BH], generated in situ, is demonstrated to promote the hydrosilylative reduction of sugars, providing a series of linear or cyclic polyols with high chemo- and regioselectivities under mild conditions. Studies of catalytic reactivity and regioselectivity with regard to the C−O bond cleavage with hydrosilanes suggest an importance of the steric environment around the anomeric carbon center of the
    Piers的硼烷[(C 6 F 5)2 BH]原位生成,可促进糖的氢化硅烷化还原,在温和条件下提供一系列具有高化学选择性和区域选择性的线性或环状多元醇。关于用氢硅烷裂解C-O键的催化反应性和区域选择性的研究表明,糖异头碳中心周围的空间环境很重要。
  • Multiple Forms of Xylose Reductase in <i>Candida intermedia</i>:  Comparison of Their Functional Properties Using Quantitative Structure−Activity Relationships, Steady-State Kinetic Analysis, and pH Studies
    作者:Bernd Nidetzky、Kaspar Brüggler、Regina Kratzer、Peter Mayr
    DOI:10.1021/jf034426j
    日期:2003.12.1
    The xylose-fermenting yeast Candida intermedia produces two isoforms of xylose reductase: one is NADPH-dependent (monospecific xylose reductase; msXR), and another is shown here to prefer NADH approximately 4-fold over NADPH (dual specific xylose reductase; dsXR). To compare the functional properties of the isozymes, a steady-state kinetic analysis for the reaction d-xylose + NAD(P)H + H(+) <--> xylitol
    木糖发酵酵母假丝酵母产生两种木糖还原酶同工型:一种是NADPH依赖性的(单特异性木糖还原酶; msXR),另一种是NADH优于NADPH(双特异性木糖还原酶; dsXR)的4倍。为了比较同工酶的功能特性,对反应中的d-木糖+ NAD(P)H + H(+)<->木糖醇+ NAD(P)(+)进行了稳态动力学分析,并进行了特异性分析测定一系列常数(k(cat)/ K(醛))的常数,以减少一系列侧链大小不同的醛的还原以及与酶的底物结合口袋的氢键结合能力。dsXR弱结合NAD(P)(+)(K(iNAD +)= 70 microM; K(iNADP +)= 55 microM)和NADH(K(i)= 8 microM)大约与NADPH(K(i)= 14 microM)。msXR显示NADPH和NADP(+)的均匀结合(K(iNADP +)大约为K(iNADPH)= 20 microM)。通过将dsXR的对数k(cat)/
  • Preparation of enantiomeric and racemic 2,3,4,5-tetrahydroxypentyl derivatives of adenine, cytosine and uracil
    作者:Antonín Holý
    DOI:10.1135/cccc19822786
    日期:——

    1-(Adenin-9-yl)-1-deoxy-DL-ribitol (III), -D-arabitol (IXa), -L-arabitol (XIVa), -DL-xylitol (XXIVa), 1-(cytosin-L-yl)-1-deoxy-D-arabitol (IXb), -L-arabitol (XIVb), 1-(uracil-1-yl)-1-deoxy-D-arabitol (IXc), -L-arabitol (XIVc) and -DL-xylitol (XXIVb) were prepared by reaction of 1-O-p-toluenesulfonyl-2,3:4,5-di-O-isopropylidenealditols Ib, VIIb, XIIb and XXIIb with sodium salts of adenine, N4-benzoylcytosine or 4-methoxy-2-pyrimidone followed by removal of the protecting groups. Condensation of the mentioned sodium salts with methyl 5-O-p-toluenesulfonyl-2,3-O-isopropylidene-β-D-ribofuranoside (IV) with subsequent acid hydrolysis and reduction with sodium borohydride afforded 1-(adenin-9-yl)-1-deoxy-L-ribitol (VIa) and 1-(cytosin-1-yl)-1-deoxy-L-ribitol (VIb). 1-(Adenin-9-yl)-1-deoxy-L-lyxitol (XVII), -L-lyxitol (XVIII) and -2-O-methyl-D-lyxitol (XXI) were prepared analogously. Acid hydrolysis of 5-(adenin-9-yl)-5-deoxy-4-O-benzyl-1,2-O-isopropylidene-α-D-xylofuranose (XXVa), followed by reduction with sodium borohydride and catalytic hydrogenation, gave 1-(adenin-9-yl)-1-deoxy-L-xylitol (XXVIb).

    1-(腺嘌呤-9-基)-1-脱氧-DL-核糖醇(III),-D-阿拉伯糖醇(IXa),-L-阿拉伯糖醇(XIVa),-DL-木糖醇(XXIVa),1-(胞嘧啶-L-基)-1-脱氧-D-阿拉伯糖醇(IXb),-L-阿拉伯糖醇(XIVb),1-(尿嘧啶-1-基)-1-脱氧-D-阿拉伯糖醇(IXc),-L-阿拉伯糖醇(XIVc)和-DL-木糖醇(XXIVb)通过将1-O-p-甲苯磺酰基-2,3:4,5-二-O-异丙基亚甲基二醇(Ib,VIIb,XIIb)和(XXIIb)与腺嘌呤、N4-苯甲酰胞嘧啶或4-甲氧基-2-嘧啶酮的钠盐反应制备,随后去除保护基。提到的钠盐与甲基5-O-p-甲苯磺酰基-2,3-O-异丙基亚-D-核糖呋喃苷(IV)缩合,随后进行酸水解和硼氢化钠还原,得到1-(腺嘌呤-9-基)-1-脱氧-L-核糖醇(VIa)和1-(胞嘧啶-1-基)-1-脱氧-L-核糖醇(VIb)。1-(腺嘌呤-9-基)-1-脱氧-L-利克糖醇(XVII),-L-利克糖醇(XVIII)和-2-O-甲基-D-利克糖醇(XXI)类似制备。5-(腺嘌呤-9-基)-5-脱氧-4-O-苄基-1,2-O-异丙基亚-D-木糖呋喃糖醇(XXVa)的酸水解,随后与硼氢化钠还原和催化氢化,得到1-(腺嘌呤-9-基)-1-脱氧-L-木糖醇(XXVIb)。
  • Production of 2'-deoxynucleosides and 2'-deoxynucleoside precursors from 2-dehydro-3-deoxy-D-gluconate
    申请人:Evologic S.A.
    公开号:EP1491549A1
    公开(公告)日:2004-12-29
    This invention relates to a process for preparing 2'-deoxynucleoside compounds or 2'-deoxynucleoside precursors using 2-dehydro-3-deoxy-D-gluconic acid (usually abbreviated as KDG) or its salts as a starting material. A variety of 2'-deoxynucleosides and their analogues are used as a starting material for synthesis or drug formulation in production of an antiviral, anticancer or antisense agent.
    这项发明涉及一种利用2-脱氢-3-去氧-D-葡糖酸(通常简称为KDG)或其盐作为起始物质制备2'-去氧核苷化合物或2'-去氧核苷化合物前体的过程。各种2'-去氧核苷和它们的类似物被用作合成或药物配方的起始物质,用于生产抗病毒、抗癌或反义核酸药剂。
查看更多